title: [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
abstract: To examine the incidence of recurrence, progression and survival in patients with grade 3 superficial bladder cancer after transurethral resection (TUR) and adjuvant intravesical instillation of Bacillus Calmette-Guérin (BCG), we retrospectively studied 39 patients with grade 3 superficial bladder cancer. Nineteen patients with high-grade superficial bladder cancer (pTa, pT1) and 5 patients with grade 3 carcinoma in situ (CIS) received intravesical instillation of BCG after transurethral resection of the bladder tumor (BCG group and CIS-BCG group). The Tokyo 172 strain BCG was given for 8 weeks, as a rule, in a dose of 80 mg in 40 ml of saline instilled into the bladder. As a control, 15 patients with grade 3 superficial bladder cancer who did not receive BCG therapy after TUR were compared (non-BCG group). Of the BCG group (n=19), 4 patients (21.1%) had recurrent tumor and 3 had invasive progression after BCG therapy and died as a result of tumor progression, while in the non-BCG group (n=15), 8 cases (53.3%) developed recurrence, only one case had progression and died of cancer. In the CIS-BCG group (n=5), 3 patients (60.0%) had recurrent tumor and 2 had invasive progression. Univariate analysis (Logrank test) demonstrated that tumor size and adjuvant instillation of BCG were associated with tumor recurrence except for carcinoma in situ, but tumor progression and survival did not differ significantly. Our results suggest that BCG therapy prevents grade 3 superficial bladder cancer (pT1, pTa) recurrence.
authors.affiliation: Department of Urology, Yokosuka Kyosai Hospital.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Yumura
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Oogo
authors.forename: Kazunori
authors.initials: K
authors.lastname: Takase
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hamano
authors.forename: Yuzo
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Sumio
authors.initials: S
authors.lastname: Noguchi
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Satomi
mesh_terms: D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D003131:Combined Modality Therapy; D015653:Cystectomy; D003986:Dibenzocycloheptenes; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D011182:Postoperative Care; D011379:Prognosis; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*
chemical_list: D001500:BCG Vaccine; D003986:Dibenzocycloheptenes; C100240:noxiptilin